Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

857
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
857
Seizures: Classification01:13

Seizures: Classification

1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Digital Intervention for Capturing the Real-Time Health Data Needed for Epilepsy Seizure Forecasting: Protocol for a Formative Co-Design and Usability Study (The ATMOSPHERE Study).

JMIR research protocols·2024
Same journal

Modeling single nucleus microglia across species identifies immune pathways and therapeutic candidates in Alzheimer's disease.

NPJ systems biology and applications·2026
Same journal

Metabolic set theory: a generalized model of microbial interactions.

NPJ systems biology and applications·2026
Same journal

Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome.

NPJ systems biology and applications·2026
Same journal

A mathematical model of folate-mediated one-carbon metabolism in Down syndrome.

NPJ systems biology and applications·2026
Same journal

A minimal mechanically consistent model of smoothly dividing disk-shaped cells.

NPJ systems biology and applications·2026
Same journal

Virtual twins and the future of human developmental biology.

NPJ systems biology and applications·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 8, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.7K

てんかんにおける発作終結のための機能障害特異的介入のモデリング

Aravind Kumar Kamaraj1,2, Matthew Parker Szuromi3

  • 1Surrey Sleep Research Centre, School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK. a.kamaraj@surrey.ac.uk.

NPJ systems biology and applications
|December 19, 2025
PubMed
まとめ
この要約は機械生成です。

この研究は、てんかんとてんかん重積状態の治療を理解するためにニューロン質量モデルを使用しています。発作終結のためには、介入が特定のてんかんの原因と一致する必要があることを示しています。

さらに関連する動画

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

9.3K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.4K

関連する実験動画

Last Updated: Jan 8, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.7K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

9.3K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.4K

科学分野:

  • 神経科学
  • 計算神経科学
  • てんかん研究

背景:

  • てんかん発作は、神経興奮と抑制の不均衡に由来します。
  • てんかん重積状態（5分以上の発作）は介入が必要です。
  • 第一選択のベンゾジアゼピン系薬は、約36％の症例で失敗します。

研究 の 目的:

  • 介入が発作終結のための脳ダイナミクスにどのように影響するかを調査する。
  • 拡張ニューロン質量モデルを使用して発作メカニズムを分析する。
  • 根本的な病態生理に基づいて最適な介入戦略を決定する。

主な方法:

  • 「維持」項を含む拡張Wilson-Cowanニューロン質量モデル。
  • さまざまな発作誘発性機能障害（過興奮、GABAの問題）をシミュレートしました。
  • さまざまな治療介入下でのモデルダイナミクスを分析しました。

主要な成果:

  • モデルは通常の活動と発作間の遷移を捉えます。
  • 過興奮、抑制枯渇、および脱分極GABAは発作を引き起こす可能性があります。
  • GABAが脱分極性でない限り、GABA作動性抑制の強化は効果的です。
  • GABA作動薬が無効な場合、レベチラセタムは効果的です。

結論:

  • 発作の病態生理は多様であり、個別化された治療が必要です。
  • 介入の効果は、治療と特定の機能障害を一致させることに依存します。
  • 根本的なメカニズムに介入を合わせることが、効果的な発作終結に不可欠です。